Table 1. Univariate and multivariate... | American Society of Hematology

Table 1.

Univariate and multivariate analysis of posttreatment MRD levels with other parameters of prognostic significance

Parameter	Progression-free survival			Overall survival
Parameter	Univariate (log-rank) P	Multivariate (Cox) P	Hazard ratio (95% CI)	Univariate (log-rank) P	Multivariate (Cox) P	Hazard ratio (95% CI)
Age* (60 y)	.513			.001	.001	2.41 (1.45-4.00)
Hemoglobin* (110 g/L)	.957			.058
Platelet* (100 × 10⁹/L)	.001	.983		.034	.168
Binet stage* (A/B vs C)	.005	.870		.001	.018	2.23 (1.14-4.33)
Prior treatment (Y/N)	.003	.159		.003	<.001	2.61 (1.61-4.23)
Treatment type	<.001	.265		.004	.886
IWCLL response	<.001	.545		.001	.585
MRD level (<0.01/0.01-0.1/0.1-1/>1%)	<.001	<.001	2.07 (1.59-2.69)	<.001	.002	1.39 (1.13-1.70)
Adverse cytogenetics* (del 17p/11q)†	.024	.013	2.00 (1.16-3.45)	.051

Parameter	Progression-free survival			Overall survival
Parameter	Univariate (log-rank) P	Multivariate (Cox) P	Hazard ratio (95% CI)	Univariate (log-rank) P	Multivariate (Cox) P	Hazard ratio (95% CI)
Age* (60 y)	.513			.001	.001	2.41 (1.45-4.00)
Hemoglobin* (110 g/L)	.957			.058
Platelet* (100 × 10⁹/L)	.001	.983		.034	.168
Binet stage* (A/B vs C)	.005	.870		.001	.018	2.23 (1.14-4.33)
Prior treatment (Y/N)	.003	.159		.003	<.001	2.61 (1.61-4.23)
Treatment type	<.001	.265		.004	.886
IWCLL response	<.001	.545		.001	.585
MRD level (<0.01/0.01-0.1/0.1-1/>1%)	<.001	<.001	2.07 (1.59-2.69)	<.001	.002	1.39 (1.13-1.70)
Adverse cytogenetics* (del 17p/11q)†	.024	.013	2.00 (1.16-3.45)	.051

Bold values are statistically significant (P < .05).

Age, hemoglobin, and platelet count; Binet stage; and cytogenetics were assessed at the time of treatment initiation.

Cytogenetic aberrations [del(17p) and/or del(11q)] were evaluated by metaphase fluorescence in situ hybridization.